Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the diseased (e.g., ischemic/reperfused), but not in the h...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenner, Gábor B., Makkos, András, Nagy, Csilla Terézia, Onódi, Zsófia, Sayour, Nabil V., Gergely, Tamás G., Kiss, Bernadett, Görbe, Anikó, Sághy, Éva, Zádori, Zoltán S., Lázár, Bernadette, Baranyai, Tamás, Varga, Richárd S., Husti, Zoltán, Varró, András, Tóthfalusi, László, Schulz, Rainer, Baczkó, István, Giricz, Zoltán, Ferdinandy, Péter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140447/
https://www.ncbi.nlm.nih.gov/pubmed/32111102
http://dx.doi.org/10.3390/cells9030551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140447/
https://www.ncbi.nlm.nih.gov/pubmed/32111102
http://dx.doi.org/10.3390/cells9030551

Ejemplares similares